Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction

Hypertension

Volumn 50, Issue 3, 2007, Pages 481-488

  Costello Boerrigter, Lisa C ^a   Boerrigter, Guido ^a   Harty, Gail J ^a   Cataliotti, Alessandro ^a   Redfield, Margaret M ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Basic science; Experimental models; Extracellular matrix; Heart failure; Kidney physiology pathophysiology; Mineralocorticoids

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; CYCLIC GMP; DEOXYCORTICOSTERONE ACETATE; MINERALOCORTICOID; THIAZIDE DIURETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOG; HEART LEFT VENTRICLE FAILURE; HEMODYNAMIC PARAMETERS; KIDNEY HYPERTROPHY; MALE; MICTURITION; NONHUMAN; PRIORITY JOURNAL; SODIUM EXCRETION; SODIUM RETENTION; STATISTICAL SIGNIFICANCE; URINALYSIS; URINARY EXCRETION; WATER RETENTION;

ANIMALS; BODY WATER; COLLAGEN; CYCLIC GMP; DESOXYCORTICOSTERONE; DIURESIS; DOGS; KIDNEY; MALE; MYOCARDIUM; NATRIURESIS; RECEPTORS, MINERALOCORTICOID; SODIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34548188807     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.088534     Document Type: Article

References (48)

1. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119:S3-S10.
2. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194 -202.
3. Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Intern Med. 2003;138:907-916.
4. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977-982.
5. Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J. 2007;28:1128-1134.
6. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
7. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
8. Stevens TL, Borgeson DD, Luchner A, Wennberg P, Redfield MM, Burnett JC Jr. A modified model of tachycardia-induced cardiomyopathy: Insights into humoral and renal adaptations. In: Spinale FG, ed. Pathophysiology of Tachycardia-Induced Heart Failure. Armonk, NY: Futura Publishing Co; 1996:133-151.
9. Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC Jr. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005;67:1723-1730.
10. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res. 1992;26:671-677.
11. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583.
12. Young MJ, Funder JW. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol. 1996;271:E883-E888.
13. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068.
14. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791-1800.
15. Ragan C, Ferrebee J, Phyfe P, Atchley D, Loeb R. A syndrome of polydipsia and polyuria induced in normal animals by desoxycorticosterone acetate. Am J Physiol. 1940;131:73-78.
16. August JT, Nelson DH, Thorn GW. Response of normal subjects to large amounts of aldosterone. J Clin Invest. 1958;37:1549-1555.
17. Nelson DH, August JT. Abnormal response of oedematous patients to aldosterone or deoxycortone. Lancet. 1959;2:883-885.
18. Schneider EG, Dresser TP, Lynch RE, Knox FG. Sodium reabsorption by proximal tubule of dogs with experimental heart failure. Am J Physiol. 1971;220:952-957.
19. Lohmeier TE, Davis JO, Freeman RH, Spielman WS, Watkins BE. Mineralocorticoid activity of 18-OH-DOC and DOCA in dogs with an aortic-caval fistula. Am J Physiol. 1976;231:56-60.
20. Villarreal D, Freeman RH, Brands MW. DOCA administration and atrial natriuretic factor in dogs with chronic heart failure. Am J Physiol. 1989;257:H739-H745.
21. Redfield MM, Aarhus LL, Wright RS, Burnett JC Jr. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation. 1993;87:2016-2022.
22. Stevens TL, Burnett JC Jr, Kinoshita M, Matsuda Y, Redfield MM. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest. 1995;95:1101-1108.
23. Lisy O, Lainchbury JG, Leskinen H, Burnett JC Jr. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001;37:1089-1094.
24. Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999;100:2443-2448.
25. Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone "escape". Hypertension. 1984;6:I183-I192.
26. Burnett JC, Haas JA, Larson MS. Renal interstitial pressure in mineralo-corticoid escape. Am J Physiol. 1985;249:F396-F399.
27. Ballermann BJ, Bloch KD, Seidman JG, Brenner BM. Atrial natriuretic peptide transcription, secretion, and glomerular receptor activity during mineralocorticoid escape in the rat. J Clin Invest. 1986;78:840-843.
28. Granger JP, Burnett JC Jr, Romero JC, Opgenorth TJ, Salazar J, Joyce M. Elevated levels of atrial natriuretic peptide during aldosterone escape. Am J Physiol. 1987;252:R878-R882.
29. Metzler CH, Gardner DG, Keil LC, Baxter JD, Ramsay DJ. Increased synthesis and release of atrial peptide during DOCA escape in conscious dogs. Am J Physiol. 1987;252:R188-R192.
30. Yokota N, Bruneau BG, Kuroski de Bold ML, de Bold AJ. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway. J Clin Invest. 1994;94:1938-1946.
31. Granger JP, Kassab S, Novak J, Reckelhoff JF, Tucker B, Miller MT. Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol. 1999;276:R197-R202.
32. Wang XY, Masilamani S, Nielsen J, Kwon TH, Brooks HL, Nielsen S, Knepper MA. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001;108:215-222.
33. Titze J, Bauer K, Schafflhuber M, Dietsch P, Lang R, Schwind KH, Luft FC, Eckardt KU, Hilgers KF. Internal sodium balance in DOCA-salt rats: a body composition study. Am J Physiol Renal Physiol. 2005;289:F793-F802.
34. Sindic A, Schlatter E. Mechanisms of action of uroguanylin and guanylin and their role in salt handling. Nephrol Dial Transplant. 2006;21:3007-3012.
35. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
36. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
37. Smilde TD, Hillege HL, Voors AA, Dunselman PH, van Veldhuisen DJ. Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. Am J Cardiol. 2004;94:240-243.
38. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-678.
39. Dries DL, Stevenson LW. Brain natriuretic peptide as bridge to therapy for heart failure. Lancet. 2000;355:1112-1113.
40. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
41. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
42. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
43. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;269:E657-E662.
44. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation. 2006;113:2851-2860.
45. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112:2940-2945.
46. Baliga RR, Ranganna P, Pitt B, Koelling TM. Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. J Card Fail. 2006;12:250-256.
47. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2:986-989.
48. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-585.